Conjustar
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developing next-generation antibody therapeutics, including bispecifics and ADCs, for precision oncology applications.
Oncology
Technology Platform
Proprietary antibody engineering and ADC platform focusing on humanization, Fc engineering, and novel linker-payload technologies for enhanced efficacy and safety.
Opportunities
Strong global demand for targeted oncology therapies with improved specificity and reduced side effects drives significant potential.
Risk Factors
High technical complexity and potential for clinical setbacks in demonstrating superiority over existing standard-of-care treatments.
Competitive Landscape
Faces intense competition from global biopharma leaders and a crowded field of Chinese biotechs in the antibody and ADC oncology space.